On August 13, Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) released new data from its Phase 1b/2a RESOLVE trial showing that odynophagia, the medical term for painful swallowing, faded dramatically in patients treated with its lead drug candidate EP-104GI. In the highest-dose cohorts, moderate to severe odynophagia fell from 62% of patients at baseline to just 25% by weeks 24 through 52, and no patient reported severe pain at either of those checkpoints. For a disease with a thin bench of treatment options, that kind of shift gets attention.
Pain Fading, Data Piling Up
The dysphagia figures tell a similar story. Moderate to severe difficulty swallowing among patients in Cohorts 7 to 9 dropped from 77% at baseline to 25% at both the 24-week and 52-week marks, with severe cases falling from 31% to zero over that same stretch. At baseline, only 15% of patients felt no odynophagia at all, and by week 52, half of them did. This is not a one-time snapshot. On April 21, Eupraxia reported that clinical remission of symptoms held in two of three patients in its highest-dose cohort through week 36, a bar first cleared at week 8.
Safety has remained clean throughout: more than 130 patients have now received EP-104GI or placebo across over 2,000 individual injection sites, with no treatment-emergent or procedure-related serious adverse events. The signal also shows up outside what patients report themselves. On May 5 and May 6, Eupraxia presented EREFS and EoEHSS data at Digestive Disease Week showing that more injections tracked with better endoscopic findings, alongside improvement in both tissue inflammation and fibrosis. Symptom relief, endoscopic scores, and tissue biopsies all pointing in the same direction is a level of consistency that supports pushing the program forward, and Eupraxia has the funding to do it: as of June 30, it held $52.4 million in cash and $81.2 million in short-term investments, enough, management says, to last into the second half of 2028.
Small Samples, Bigger Bills
All of this still comes from the open-label, uncontrolled portion of RESOLVE, where both patients and doctors know who received the drug. That matters because the real test, a randomized, placebo-controlled Phase 2b trial, is still recruiting, with interim results not due until the fourth quarter of 2026. Sample sizes also shrink right at the time points that make the best headlines: only eight patients remained in the week-52 odynophagia and dysphagia analysis, and the Cohort 9 remission finding rests on just three patients. Running the larger trial is getting more expensive too. Eupraxia’s net loss widened to $14.5 million in the second quarter of 2026, up from $8.7 million a year earlier, which the company tied to doubling the size of the RESOLVE Part 2 trial along with higher general and administrative costs.
The company is also mid-reorganization. On July 13, Eupraxia said it would shift operations from Victoria to a two-hub structure split between Vancouver and Seattle, and Amanda Malone stepped down as Chief Scientific and Operating Officer as part of that move. Fresh leadership has arrived since, including a new Chief Medical Officer in May and three new board members in July, but absorbing that much change while running a pivotal trial carries its own risk. And with 65.5 million common shares outstanding alongside preferred shares and pre-funded warrants, the capital structure has more moving parts than a plain common-stock story.
Funds Are Buying In
Hedge fund interest in Eupraxia has been building. The number of funds holding a position rose from 19 in the prior quarter to 24 most recently, a shift that points toward institutional buyers warming up to the story ahead of the Phase 2b interim data due in the fourth quarter of 2026.
The Real Test Awaits
Eupraxia keeps stacking data that all points the same way: less pain, less difficulty swallowing, and tissue that looks healthier on endoscopy and biopsy alike, and that consistency is likely what has hedge funds adding shares even before a controlled trial reads out. The tension is straightforward. An open-label study run by researchers who know which patients got the drug carries a built-in optimism that a placebo-controlled trial does not share, and that is exactly the test Eupraxia now faces. A widening net loss and a mid-stream leadership shakeup add real execution risk to the wait.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
